Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05511428 · OUTCOME

Patient Perceptions of Home Based Anti-neoplastic Therapy

Home Based Daratumumab Administration for Patients With Multiple Myeloma · Source last updated 2025-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Cycle 3 through Cycle 6, days 57-169

What was measured

Patient perceptions of home based anti-neoplastic therapy will be measured through semi-structured interviews.

Groups in this outcome

Treatment (daratumumab and hyaluronidase-fihj)

Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Daratumumab and Hyaluronidase-fihj: Given SC Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies Interview: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (daratumumab and hyaluronidase-fihj)19

Reported measurements

Positive : Familiarity
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)2Not reportedNot reportedNot reportedNot reported
Positive : Overall Comfort
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)3Not reportedNot reportedNot reportedNot reported
Positive : Ability to Rest After Treatment
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)3Not reportedNot reportedNot reportedNot reported
Positive : More Time in the Day for Work/Other Activities
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)3Not reportedNot reportedNot reportedNot reported
Positive : Eliminated Travel Inconveniences
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)3Not reportedNot reportedNot reportedNot reported
Positive : Acceptability of Home Blood Draws
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)2Not reportedNot reportedNot reportedNot reported
Positive : Satisfaction with Home Infusion Staff
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)2Not reportedNot reportedNot reportedNot reported
Negative : Wait Times
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Positive : Familiarity
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Positive : Overall Comfort
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Positive : Ability to Rest After Treatment
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Positive : More Time in the Day for Work/Other Activities
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Positive : Eliminated Travel Inconveniences
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Positive : Acceptability of Home Blood Draws
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Positive : Satisfaction with Home Infusion Staff
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Negative : Wait Times
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
Patient perceptions of home based anti-neoplastic therapy will be measured through semi-structured interviews.
groups
  1. description
    Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Daratumumab and Hyaluronidase-fihj: Given SC Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies Interview: Ancillary studies
    id
    OG000
    title
    Treatment (daratumumab and hyaluronidase-fihj)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Cycle 3 through Cycle 6, days 57-169
title
Patient Perceptions of Home Based Anti-neoplastic Therapy
type
OTHER_PRE_SPECIFIED
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice